WCM Investment Management
BMRN icon

WCM Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

WCM Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
22,930
+4,100
+22% +$225K ﹤0.01% 216
2026
Q1 		$1.03M Sell
18,830
-46
-0.2% -$2.68K ﹤0.01% 234
2025
Q4 		$1.11M Buy
18,876
+9,251
+96% +$504K ﹤0.01% 221
2025
Q3 		$520K Buy
9,625
+320
+3% +$18.3K ﹤0.01% 215
2025
Q2 		$513K Sell
9,305
-8,048
-46% -$474K ﹤0.01% 208
2025
Q1 		$1.24M Sell
17,353
-187
-1% -$12.6K ﹤0.01% 242
2024
Q4 		$1.15M Buy
17,540
+595
+4% +$39.9K ﹤0.01% 251
2024
Q3 		$1.2M Buy
16,945
+10,485
+162% +$876K ﹤0.01% 249
2024
Q2 		$539K Buy
6,460
+1,593
+33% +$133K ﹤0.01% 227
2024
Q1 		$425K Buy
4,867
+76
+2% +$6.8K ﹤0.01% 218
2023
Q4 		$465K Buy
+4,791
New +$424K ﹤0.01% 220

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

WCM Investment Management's BMRN Position: Q2 2026 in Review

WCM Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q2 2026, buying an estimated $225K and bringing the position to 22,930 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #216.

WCM Investment Management first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • WCM Investment Management held 22,930 shares of BioMarin Pharmaceuticals worth $1.32M as of Q2 2026.
  • WCM Investment Management bought 4,100 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of WCM Investment Management's portfolio in Q2 2026, its #216 holding.
  • WCM Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on WCM Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.